IBRX FY 2019 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$43,000-8.5% YoY

Gross Profit

-$9M-20858.1% margin

Operating Income

-$67M-155597.7% margin

Net Income

-$66M-152997.7% margin

EPS (Diluted)

$-0.42

Cash Flow

Operating Cash Flow

-$152M

Free Cash Flow

-$156M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$143M

Total Liabilities

$22M

Stockholders' Equity

$121M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$43,000	$47,000	-8.5%
Gross Profit	-$9M	$3M	-384.1%
Operating Income	-$67M	-$98M	+32.0%
Net Income	-$66M	-$96M	+31.6%